Oxford Gene Technology acquires Sense Proteomic Ltd. to develop biomarker development business
Using its proprietary protein array platform, Sense Proteomic has identified autoantibody signatures with the potential to improve disease diagnosis and prognosis, to identify stage of a disease by monitoring the changes in autoantibody production during disease progression, to monitor the response to therapeutic interventions and to improve clinical outcomes by the stratification of patients for clinical trials and treatment.
Sense Proteomic has identified biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus, and has other biomarker discovery programmes in progress.
Mike Evans, OGT’s CEO, said: “Sense Proteomic’s highly skilled scientific team has already demonstrated significant progress in developing biomarker panels based on its novel functional protein array platform. This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.